Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 August 2020 | Story Amanda Tongha | Photo NSFAS

Applications for the National Student Financial Aid Scheme (NSFAS) 2021 are now open.  

The NSFAS application cycle will run for a period of four months starting from 3 August to 30 November 2020. 

NSFAS applications are open to students from poor and working-class backgrounds who wish to further their studies at any public Technical and Vocational Education and Training (TVET) college or university. To qualify for NSFAS funding, the applicant must be a South African citizen; come from a family with a combined annual household income of not more than R350 000; for students with a disability, a combined annual household income of not more than R600 000. 

Applications for 2021 funding will be completed online via the myNSFAS portal as per previous years. 

New applicants need a copy of their ID or birth certificate to register and create a myNSFAS account or profile on the myNSFAS portal. Applicants with existing accounts must log on to their accounts to complete an application. Applicants are not allowed to create more than one profile on the portal. The applicant will be required to give consent to NSFAS to verify their personal information with third parties and will not be able to create a profile without giving this consent. This feature allows NSFAS to conduct a three-step verification process with the Department of Home Affairs (DHA), where an ID number will be linked to the name and surname of the applicant and the parents' details. 

In response to the status quo due to the COVID-19 pandemic, applicants will not be required to submit or upload the consent form; however, they will have to grant consent electronically during the application process, along with accepting the terms and conditions for funding. 

Applicants will, however, still be required to submit their supporting documents, comprising a copy of own ID; parents’/guardian's proof of income; copies of parents’/guardian's ID; and/or Annexure A for applicants with disabilities. 

Qualifying students are urged to make use of this opportunity and apply for funding in time. 

 
 

News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept